Plasma Biomarkers P-DAC, V1

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

NCT02501902 ·Status: COMPLETED ·Phase: PHASE1

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

NCT06574620 ·Status: RECRUITING ·Phase: NA

BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC")

NCT03311776 ·Status: RECRUITING

GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES

NCT06102889 ·Status: ENROLLING_BY_INVITATION

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

NCT01783171 ·Status: COMPLETED ·Phase: PHASE1

Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial

NCT07034703 ·Status: NOT_YET_RECRUITING

RNA Precision Oncology in Advanced Pancreatic Cancer

NCT04476537 ·Status: TERMINATED ·Phase: NA

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

NCT06206876 ·Status: WITHDRAWN ·Phase: PHASE1

Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma

NCT01474564 ·Status: COMPLETED

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

NCT06151223 ·Status: RECRUITING

Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.

NCT06397846 ·Status: RECRUITING ·Phase: NA

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

NCT02869802 ·Status: RECRUITING

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

NCT06287749 ·Status: RECRUITING

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06673017 ·Status: RECRUITING ·Phase: PHASE1

Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

NCT02414100 ·Status: WITHDRAWN

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

NCT02921022 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma

NCT02974764 ·Status: COMPLETED

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

NCT03727880 ·Status: COMPLETED ·Phase: PHASE2

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

NCT05475366 ·Status: RECRUITING ·Phase: NA

Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers

NCT04449406 ·Status: ACTIVE_NOT_RECRUITING

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

NCT06122896 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

NCT05132504 ·Status: RECRUITING ·Phase: PHASE2

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

NCT01983410 ·Status: ACTIVE_NOT_RECRUITING

A Clinical Study of BRCA and DNA Damage Repair Genes in Blood Samples of Chinese Pancreatic Cancer Patients

NCT05138302 ·Status: UNKNOWN

Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

NCT04821219 ·Status: WITHDRAWN ·Phase: NA